Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives. (2020)

• Record Type: Journal Article
• Authors: Reimann, Hauke; Ngo, Quoc Anh; Stopper, Helga; Hintzsche, Henning
• Is Part Of: Toxicology reports. Volume 7(2020)
• Page Start: 1588
• Page End: 1591
• Publication Date: 2020
• Subjects: Celecoxib -- DNA damage -- Micronucleus test -- Chemoprevention; Toxicology -- Periodicals; Clinical toxicology -- Periodicals; Drug-Related Side Effects and Adverse Reactions; Hazardous Substances; Poisoning; Toxicology; Electronic journals; Periodicals; Periodicals; 571.9505
• DOI: 10.1016/j.toxrep.2020.11.004
• Languages: English
• ISSNs: 2214-7500

Abstract

Highlights: New derivatives of celecoxib can improve beneficial effects with better safety profile. DNA damage in form of micronuclei has not been observed after treatment with celecoxib or any derivative. Further development of celecoxib derivatives for chemoprevention may be promising. Abstract: Celecoxib is used widely for the acute treatment of pain and for pain relief in various diseases. Furthermore, it shows potential in chemoprevention, although chronic treatment with celecoxib could lead to adverse effects like cardiovascular events. New derivatives of celecoxib were synthesised that may be suitable as chemopreventive agent without inducing adverse effects. Critical endpoint for a safe use of pharmaceuticals is genotoxicity after application. A standard test for the assessment of genotoxicity is the cytokinesis-block micronucleus assay, that evaluates the number micronuclei after treatment of cells with a test compound as biomarker for DNA damage. Various promising derivatives of celecoxib have been assessed with the cytokinesis-block micronucleus assay in HeLa-H2B-GFP cells. It could be demonstrated, that neither celecoxib nor its derivatives were genotoxic in this assay and therefore celecoxib derivatives could be developed further for a safe use as chemopreventive agent.